Franklin Street Advisors Inc. NC Makes New $201,000 Investment in Fresenius Medical Care AG (NYSE:FMS)

Franklin Street Advisors Inc. NC acquired a new stake in shares of Fresenius Medical Care AG (NYSE:FMS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,896 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Rhumbline Advisers grew its holdings in shares of Fresenius Medical Care by 6.7% during the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after buying an additional 1,128 shares during the last quarter. Caprock Group LLC acquired a new stake in shares of Fresenius Medical Care in the second quarter worth $208,000. American Century Companies Inc. raised its holdings in shares of Fresenius Medical Care by 29.3% during the second quarter. American Century Companies Inc. now owns 24,046 shares of the company’s stock worth $459,000 after purchasing an additional 5,445 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Fresenius Medical Care by 14.4% during the second quarter. Dimensional Fund Advisors LP now owns 12,539 shares of the company’s stock valued at $239,000 after purchasing an additional 1,576 shares during the period. Finally, Wulff Hansen & CO. boosted its holdings in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on FMS. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They set a “strong-buy” rating on the stock. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Finally, Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday.

Fresenius Medical Care Trading Up 0.7 %

NYSE:FMS traded up $0.15 on Friday, hitting $22.55. The stock had a trading volume of 69,266 shares, compared to its average volume of 182,145. The stock has a market cap of $13.23 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 0.95 and a beta of 0.92. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average price of $22.45 and a two-hundred day moving average price of $20.74. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $24.31.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.